Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Completes Acquisition of Correlogic Ovarian Cancer Dx Business

NEW YORK (GenomeWeb News) – Vermillion today said that it has completed the acquisition of the assets associated with Correlogic Systems' ovarian cancer diagnostics business for $435,000 in cash.

Vermillion said early last month that it had acquired the assets of Correlogic, a firm operating under Chapter 11 bankruptcy protection.

According to Austin, Texas-based Vermillion, the assets include more than 1,000 prospectively collected diagnostic samples from ovarian tumor studies, three biomarker-related US patents that are pending, software, and other intellectual property. The firm plans to use the assets in advancing its ovarian cancer testing franchise, including in the development of its OVA2 next-generation test.

"While Vermillion notes the loss of a substantial competitor, the acquisition of these assets will enhance our development efforts, and offers significant savings in terms of time and cost," Vermillion CEO Gail Page said in a statement.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.